ACTBRCA®

Precision Medicine to Analyze BRCA1/2 Genetic Information

Provides Opportunities for PARP Inhibitors

In the history of cancer treatment, precision medicine is now endorsed as a modern and preferred way for a healthcare system to take care of its cancer patients. Challenges in identifying the right drug for every cancer patient, as new drugs are emerging for specific genomic mutations, can be tackled strategically by obtaining a cancer patient's unique cancer genomic profile. The acceleration of oncology drug approvals and the modernization of clinical trials with biomarker-based patients have progressed well, as these have been commitments of the US FDA from 2018. The wave of precision medicine has also increased the approvals of companion diagnostics, which has resulted in ACT Genomics' genomic profiling service being on the waiting list for US FDA approval.

Why You Need to Know About Precision Medicine

The top global pharma companies are increasingly conducting clinical trials using precision medicine, which requires a cancer patient's genomic information through genomic profiling. This evolution has been felt by most hospitals, so it is increasingly more likely that genomic profiling will be required if you wish to try a new treatment option.

Can I Use PARP Inhibitors to Destroy My Cancer?

As the name suggests, precision medicine does away with much of the hardships associated with untargeted treatments. PARP Inhibitors are one example of how a patient can overcome treatment difficulties less painfully by targeting the vulnerable part of a cancer cell - its' DNA repair functions. Once the DNA repair mechanism of a cancer cell has some gene defects, such as BRCA and other HRR genes, and a homologous recombination deficiency (HRD) is formed, it's time for PARP inhibitors to clean up the mess. An effective and oral dose makes cancer treatment easy, and ovarian and HER2-negative breast cancer patients who previously suffered from the pain of multiple surgeries and ineffective chemotherapies can turn the tables on their fight against cancer.

Common Problems Associated with Cancer Treatment

∙ Chemotherapy and surgery are the only options recommended by the NCCN guidelines or single-gene testing results.
∙ Complications and metastases make it difficult to determine an appropriate drug.
∙ Ineffective treatment and cancer relapse after targeted therapy.

More Comprehensive Diagnostic Solutions Than Traditional BRCA Gene Testing

Through next-generation sequencing (NGS), ACTBRCA^® decodes BRCA1/2 cancer genes to map drug options based on thorough clinical research and is not limited to a single clinical treatment guideline. ACTBRCA^® determines the growth mechanism on a genomic level to provide more treatment strategy options with a higher success rate.

ACTBRCA^® is suitable for ovarian and breast cancers. As single gene testing only provides very limited results, NGS genomic profiling can detect any special genomic mutations to result in a more effective treatment.

Treatment Advantages from DNA Repair Gene Testing

✔ More humane process: Avoids multiple biopsies and the time cost associated with single-gene testing, as only a small specimen is required for the simultaneous detection of BRCA1/2.

✔ More ideal treatment: Evaluates the use of PARP inhibitor.

✔ More intelligent budgeting: Evaluates options before treatment, according to genomic information, to ensure success rate and avoid wasting of funds.

Type of patients
∙ Considering PARP inhibitor treatment
∙ Newly diagnosed, advanced, recurrent and metastatic cancer

Specimen requirements
Tumor tissue (FFPE) or blood

Turnaround time
10 working days*